Karen Fancher, PharmD, BCOP, associate professor of pharmacy practice at Duquesne University and clinical oncology specialist ...
A pragmatic cluster-randomized trial across 8 CHC sites (Boston and Los Angeles) enrolled 5127 adults aged 45–75 years overdue for screening, randomizing clinics to FIT versus FIT-DNA outreach.
Site-neutral payment has advanced from E&M to drug administration codes, but stakeholders warn rapid, simultaneous policy ...
Rose Gerber, MS, director of patient advocacy and education at the Community Oncology Alliance (COA) Patient Advocacy Network ...
Advanced therapies are pressuring reimbursement and necessitating real-world durability data and new payment models, said ...
Specialty pharmacy workflows must account for longer, more complex affordability calls, with copay-shock interactions ...
Innovations in pharmacy are already delivering results, but there is still work to do to evolve the ecosystem, said Ryan ...
Adoption metrics show a wide gap between declared AI priority and production deployment in health care, compounded by limited ...
Lekan Ajayi, PharmD, explains how remote therapy monitoring keeps patients with cancer on track with their care and reduces ...
For Diana Verrilli, MS, senior vice president and general manager of Navista, the Community Oncology Alliance’s newly ...
Part B negotiations introduce buy-and-bill economics, ASP and 340B interactions, and heightened risk of non-medical switching ...
Randomized assignment to trabeculectomy versus drops enabled comparative assessment of visual field, IOP, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results